NASDAQ:ACRV Acrivon Therapeutics (ACRV) Stock Forecast, Price & News $12.12 -0.43 (-3.43%) (As of 09:35 AM ET) Add Compare Share Share Today's Range$12.12▼$12.8650-Day Range$8.38▼$14.0952-Week Range$8.06▼$25.47Volume2,334 shsAverage Volume55,945 shsMarket Capitalization$265.79 millionP/E RatioN/ADividend YieldN/APrice Target$22.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acrivon Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.5% Upside$22.60 Price TargetShort InterestBearish2.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.76) to ($3.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector816th out of 1,009 stocksPharmaceutical Preparations Industry410th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingAcrivon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.60, Acrivon Therapeutics has a forecasted upside of 86.5% from its current price of $12.12.Amount of Analyst CoverageAcrivon Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.83% of the float of Acrivon Therapeutics has been sold short.Short Interest Ratio / Days to CoverAcrivon Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldAcrivon Therapeutics does not currently pay a dividend.Dividend GrowthAcrivon Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRV. Previous Next 2.7 News and Social Media Coverage News SentimentAcrivon Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acrivon Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ACRV on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added Acrivon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acrivon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions63.82% of the stock of Acrivon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acrivon Therapeutics are expected to decrease in the coming year, from ($2.76) to ($3.43) per share.Price to Book Value per Share RatioAcrivon Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Acrivon Therapeutics (NASDAQ:ACRV) StockAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The AP3 platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients predicted to benefit from its drug candidates. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is being advanced in a potentially registrational Phase 2 trial across various tumor types. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. The company was incorporated in 2018 and is based in Watertown, Massachusetts.Read More Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Stock News HeadlinesMay 25, 2023 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $22.60 Average PT from BrokeragesMay 12, 2023 | americanbankingnews.comAcrivon Therapeutics, Inc.'s (NASDAQ:ACRV) Lock-Up Period Set To End on May 15thMay 30, 2023 | Edge On The Street (Ad)Is Graphite the New Lithium?Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.May 10, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Acrivon Therapeutics, Inc. (ACRV)May 9, 2023 | finance.yahoo.comQ1 2023 Akoya Biosciences Inc Earnings CallMay 9, 2023 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsMay 9, 2023 | finance.yahoo.comAcrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial CancerMay 9, 2023 | finance.yahoo.comAcrivon Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsMay 30, 2023 | Edge On The Street (Ad)New "Mined in America" Lithium Opportunities?The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.May 9, 2023 | americanbankingnews.comAcrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at BMO Capital MarketsMay 9, 2023 | markets.businessinsider.comAcrivon Therapeutics, Inc. (ACRV) Receives a Buy from BMO CapitalMay 7, 2023 | finance.yahoo.comWe Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business GrowthMay 3, 2023 | msn.comHC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy RecommendationMay 2, 2023 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $22.00 Average PT from AnalystsApril 30, 2023 | americanbankingnews.comAcrivon Therapeutics (NASDAQ:ACRV) Now Covered by Analysts at LADENBURG THALM/SH SHApril 25, 2023 | finance.yahoo.comAcrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor ConferenceApril 25, 2023 | americanbankingnews.comAcrivon Therapeutics, Inc. (NASDAQ:ACRV) to Post Q1 2023 Earnings of ($0.42) Per Share, HC Wainwright ForecastsApril 24, 2023 | finance.yahoo.comAcrivon Therapeutics to Host Virtual Investor Event on May 1, 2023April 23, 2023 | americanbankingnews.comHC Wainwright Begins Coverage on Acrivon Therapeutics (NASDAQ:ACRV)April 20, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy RecommendationApril 18, 2023 | finance.yahoo.comAcrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days ConferenceMarch 28, 2023 | finanznachrichten.deAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsMarch 28, 2023 | finance.yahoo.comAcrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsMarch 28, 2023 | finance.yahoo.comAcrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsMarch 20, 2023 | msn.comAcrivon Therapeutics stock plunges nearly 30%March 6, 2023 | finance.yahoo.comAcrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 1, 2023 | barrons.comAcrivon Therapeutics Inc.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACRV Company Calendar Last Earnings3/28/2023Today5/30/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRV CUSIPN/A CIK1781174 Webwww.acrivon.com Phone617-207-8979FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$22.60 High Stock Price Forecast$25.00 Low Stock Price Forecast$17.00 Forecasted Upside/Downside+80.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio21.82 Quick Ratio21.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.16 per share Price / Book1.54Miscellaneous Outstanding Shares21,930,000Free FloatN/AMarket Cap$275.22 million OptionableNot Optionable BetaN/A Key ExecutivesDr. Peter Blume-Jensen M.D. (Age 61)Ph.D., Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer Comp: $645kMs. Kristina Masson Ph.D. (Age 43)Co-Founder, Exec. VP of Bus. Operations, Treasurer, Sec. & Director Dr. Eric J. Devroe Ph.D. (Age 45)Chief Operating Officer Comp: $375kMr. Erick Gamelin M.D. (Age 66)Ph.D., Chief Medical Officer Comp: $480.72kMr. Rasmus Holm-Jorgensen (Age 52)Chief Financial Officer Ms. Katharine Peterson CPAVP of Fin. & AccountingMr. Bruce CloseVP of Quality & ComplianceMs. Mary-Alice Miller J.D. (Age 49)Gen. Counsel Ms. Crystal MercadoGlobal Head of HRDr. Jesper V. Olsen Ph.D.Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory BoardMore ExecutivesKey CompetitorsRallybioNASDAQ:RLYBI-MabNASDAQ:IMABAdicet BioNASDAQ:ACETNuvectis PharmaNASDAQ:NVCTPrelude TherapeuticsNASDAQ:PRLDView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 6,630 shares on 5/18/2023Ownership: 0.030%New York State Common Retirement FundBought 2,206 shares on 5/18/2023Ownership: 0.010%Geode Capital Management LLCBought 175,404 shares on 5/16/2023Ownership: 0.800%State Street CorpBought 85,339 shares on 5/16/2023Ownership: 0.389%Susquehanna International Group LLPBought 32,262 shares on 5/16/2023Ownership: 0.147%View All Insider TransactionsView All Institutional Transactions ACRV Stock - Frequently Asked Questions Should I buy or sell Acrivon Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRV shares. View ACRV analyst ratings or view top-rated stocks. What is Acrivon Therapeutics' stock price forecast for 2023? 7 equities research analysts have issued 12 month target prices for Acrivon Therapeutics' shares. Their ACRV share price forecasts range from $17.00 to $25.00. On average, they predict the company's share price to reach $22.60 in the next twelve months. This suggests a possible upside of 80.1% from the stock's current price. View analysts price targets for ACRV or view top-rated stocks among Wall Street analysts. How have ACRV shares performed in 2023? Acrivon Therapeutics' stock was trading at $11.52 at the beginning of 2023. Since then, ACRV shares have increased by 8.9% and is now trading at $12.55. View the best growth stocks for 2023 here. When is Acrivon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our ACRV earnings forecast. How were Acrivon Therapeutics' earnings last quarter? Acrivon Therapeutics, Inc. (NASDAQ:ACRV) posted its quarterly earnings data on Tuesday, March, 28th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.30. When did Acrivon Therapeutics IPO? (ACRV) raised $100 million in an initial public offering on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. What is Acrivon Therapeutics' stock symbol? Acrivon Therapeutics trades on the NASDAQ under the ticker symbol "ACRV." When did the company's lock-up period expire? Acrivon Therapeutics' lock-up period expired on Monday, May 15th. Acrivon Therapeutics had issued 7,550,000 shares in its initial public offering on November 15th. The total size of the offering was $94,375,000 based on an initial share price of $12.50. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. Who are Acrivon Therapeutics' major shareholders? Acrivon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (4.05%), Federated Hermes Inc. (2.80%), BlackRock Inc. (2.16%), Geode Capital Management LLC (0.80%), State Street Corp (0.39%) and Charles Schwab Investment Management Inc. (0.27%). Insiders that own company stock include Ltd Chione and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Acrivon Therapeutics? Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acrivon Therapeutics' stock price today? One share of ACRV stock can currently be purchased for approximately $12.55. How much money does Acrivon Therapeutics make? Acrivon Therapeutics (NASDAQ:ACRV) has a market capitalization of $275.22 million. How can I contact Acrivon Therapeutics? The official website for the company is www.acrivon.com. The company can be reached via phone at 617-207-8979 or via email at asantos@wheelhouselsa.com. This page (NASDAQ:ACRV) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrivon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.